Characteristics of Breast Cancers with Concurrent Focal Thyroid Incidentalomas Using 18F-Fluorodeoxyglucose Positron Emission Tomography

JungSun Lee
Department of Surgery, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea

INTRODUCTION

The overall reported incidence of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) or PET/computed tomography (PET/CT)-detected thyroid incidentalomas varies from 0.2% to 8.9%, whereas the presence of thyroid cancer in these incidental lesions can range from 8% to 64% [1,2]. Thyroid incidentalomas may represent benign disease, primary malignancy, or metastases [3]. Both thyroid and breast cancers are more frequent in women than in men, and it has been suggested that estrogen plays a role in the tumorigenesis of both cancers. Several studies have demonstrated that there is an increased risk of breast cancer in patients with thyroid dysfunction and thyroid cancer [4]. As 18F-FDG PET/CT is widely used in the diagnosis, staging, and metastatic workups of patients with neoplastic disease, the incidence of 18F-FDG PET-detected incidentalomas is increasing [5,6]. In Korea, thyroid cancer is the most common female cancer, followed by breast cancer [7]. There have been few studies of 18F-FDG PET/CT-detected thyroid incidentalomas in breast cancer patients [1,8]. Guidelines are needed to manage thyroid incidentalomas detected during treatment for breast cancer.

Our study aimed to evaluate (1) the incidence of focal thyroid incidentalomas identified on 18F-FDG PET for breast cancer compared with the incidence in healthy women; (2) any correlation between the clinicopathological characteristics of breast cancers with concurrent focal thyroid incidentalomas; and (3) the malignant potential of 18F-FDG PET/CT-detected focal thyroid incidentalomas.

METHODS

Patient selection

We reviewed a database of patients and healthy subjects who underwent 18F-FDG PET/CT between March 2010 and February 2012 at our...
F-FDG PET/CT imaging and imaging analysis

All patients fasted and rested for at least 6 hours before undergoing 18F-FDG PET/CT (Biograph 64; Siemens, Erlangen, Germany) scanning. Serum glucose levels were less than 200 mg/dL before 18F-FDG administration. A total of 4.5 MBq/kg of 18F-FDG was injected into a vein contralateral to the tumor side. At 60 minutes after 18F-FDG injection, a 3-minute static emission study was performed at the transmission position (early phase), another study for the delayed phase was performed 120 minutes after the injection, and whole body imaging was performed from the base of the skull to the mid thighs. Low-dose whole body CT was performed before the emission scan for CT attenuation correction instead of a transmission scan. These data were also used for anatomic localization of the PET emission image. The attenuation-corrected PET images were reconstructed with an ordered subset expectation maximization iterative algorithm. The resulting in-plane image resolution of the axial view had a full width of 5.8 mm at half maximum. Imaging data were obtained with a Biograph Sensation 16 (Biograph 64) scanner, which produces transaxial, coronal, and sagittal reconstructions of CT, PET, and fusion of PET/CT data for interpretation. The Biograph scanner combines a 16-detector-row spiral CT scanner (Somatom Emotion; Siemens) and a high resolution PET scanner with 4.5-mm spatial resolution and three-dimensional image acquisition. A multimodality computer platform was used for image review and manipulation. After scatter and decay correction and reorientation in axial, sagittal, and coronal planes, the 18F-FDG PET/CT images were reviewed by an experienced nuclear physician. All patients were studied in the supine position, oriented slightly obliquely and contralateral to the tumor side. To calculate the maximum standardized uptake value (SUVmax), circular regions of interest (ROI) were manually drawn on the attenuation-corrected emission images throughout the axial planes in which a suspicious lesion could be delineated.

Image analysis

On 18F-FDG PET/CT images, thyroid uptake was considered to be present when there was increased uptake in the thyroid gland compared to the physiological background. For the visual analysis, abnormal FDG uptake was defined as substantially greater activity than in the aortic blood on attenuation-corrected images. Metabolic activity within the thyroid glands was determined. Focal thyroid uptake was defined as uniform distribution of the tracer above the background throughout one lobe. All PET/CT images were read directly from the screen of the computer workstation, and CT findings were recorded for abnormalities, including the heterogeneity of the thyroid parenchyma (homogeneous or heterogeneous) and the pattern of calcification (nodular, globular, amorphous, or linear) based on the CT portion of the PET/CT scan. When a space-occupying lesion was present, its exact size and the solid or cystic pattern were confirmed. Semiquantitative evaluation was performed using a Syngo MultiModality Workplace (Siemens AG, Berlin, Germany). A ROI was drawn on the fused PET/CT image to measure the SUV of the tumor. The SUV is defined as follows: (peak kBq/mL in ROI)/(injected activity/g of body weight).

To calculate the SUVmax, manually defined circular ROIs were drawn on the attenuation-corrected emission images throughout the axial plane on which a suspicious lesion could be delineated. We defined 18F-FDG PET/CT-detected focal thyroid incidentalomas as the presence of focal FDG uptake in the thyroid including very tiny foci of metabolic activity within the thyroid glands was determined. Focal thyroid uptake was defined as substantially greater activity than in the aortic blood on attenuation-corrected images.

Immunohistochemical staining of breast cancer

Immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was performed using arrayed tissue blocks. Briefly, 5 μm-thick, formalin-fixed, paraffin-embedded tissue sections were obtained using a microtome, transferred to adhesive slides, and dried at 62°C for 30 minutes. Sections were incubated, using a benchmark automated immunostaining device (Ventana Medical Systems, Tucson, Arizona).
USA), with primary antibodies against ER (1:50 dilution; Diona, Seoul, Korea), PR (1:100 dilution; Diona), and HER2 (1:250 dilution; DAKO, Glostrup, Denmark), followed sequentially by incubation with biotinylated antimouse immunoglobulin and peroxidase-labeled streptavidin, using 3,3′-diaminobenzidine chromogenic as the substrate. ER and PR staining were scored using the Allred scoring system on a scale from 0 to 8 for nuclear staining only. The intensity score and percentage score were added together to obtain the Allred score. Allred scores of 0 to 2 were classified as negative and Allred scores of 3 to 8 were classified as positive. HER2 was scored using the current American Society of Clinical Oncology/College of American Pathologist guidelines. Membranous immunoreactivity was scored (0 and 1+ indicates negative; 2+, indeterminate; and 3+, positive for over-expression) and the percentage of tumor cells staining positive was shown as raw score ranging from 0% to 100% [9]. Samples were considered positive for HER2 when strong (3+) membranous staining was observed in at least 10% of tumor cells, whereas those with staining of grades 0 to 2+ were regarded as negative. Tissue samples of HER2 2+ breast cancers underwent silver in situ hybridization analysis. For practical considerations in a hospital setting, as a substitute for gene expression profiling, the use of immunohistochemical surrogate panels of ER, PR, and HER2 has been proposed to potentially differentiate between the subtypes [10].

Figure 1. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). (A) Anterior projection, (B) lateral projection, and (C) transaxial planes. A hypermetabolic lesion is seen in the left lobe (blue arrows) of thyroid with standardized uptake value (SUV) of 3.9 and right breast (red arrows) with SUV of 6.0 concurrently. Corresponding CT images of left thyroid incidentaloma (white arrow) was also obtained.

Cytological confirmation of 18F-FDG PET/CT–detected focal thyroid incidentalomas

Fine-needle aspiration biopsy (FNAB) is recommended, regardless of the size of the nodule, if it presents sonographic signs suggestive of a malignancy according to the guidelines of the National Cancer Institute [11].

FNAB was performed with a 21-gauge needle on a 10 mL syringe under ultrasound guidance. A cytological diagnosis was made by experienced cytopathologists in our institution. Cytological diagnosis was as follows: (1) nondiagnostic (applies to specimens that are unsatisfactory due to blood, overlaid thick or air-dried smears, or an inadequate number of follicular cells); (2) benign; (3) atypia of undetermined significance (results of proliferating cell nuclear antigen cytology were not easily classified into benign, suspicious, or malignant categories); (4) follicular neoplasm (findings of high cellularity and scant or absent colloid); (5) suspicious for malignancy (only one or two characteristic features of papillary thyroid carcinoma were present, or a malignant diagnosis could not be made with certainty; (6) malignant (whenever the morphologic features were conclusive for malignancy) [12].

Data collection

The following data were recorded for all breast cancer patients: age, body mass index, number of lymph node metastases, tumor size, his-
tological type, lymph vascular invasion (yes/no), extensive intraductal component (yes/no), p53 expression (yes/no), Ki-67 expression >14% (yes/no), ER status, PR status, HER2 status (positive/negative), thyroid ultrasonographic findings, cytological results of focal thyroid incidentalomas, and SUVmax. We also collected the medical records of healthy women with focal thyroid incidentalomas, such as thyroid ultrasonographic findings, cytological results of the focal thyroid incidentaloma, and SUVmax. We compared the incidence of 18F-FDG PET-detected focal thyroid incidentalomas between patients with breast cancer and healthy women. We compared the clinicopathological findings between patients with and without 18F-FDG PET-detected focal thyroid incidentalomas.

Statistical analyses
The statistical analyses were performed using SAS version 8.2 (SAS Institute Inc., Cary, USA). Clinical and demographic characteristics were compared using Pearson chi-squared test. SUVmax values were compared using the Mann-Whitney test. All p-values reported are two-tailed, and a p-value of less than 0.05 was considered statistically significant.

RESULTS
Incidence of thyroid incidentalomas on 18F–FDG PET/CT: comparisons between primary breast cancer patients and healthy female subjects
In 489 breast cancer patients, 46 patients (9.4%) had a focal thyroid incidentaloma detected by pretreatment 18F-FDG PET/CT. Seventeen healthy women (5.9%) had an 18F-FDG PET/CT-detected focal thyroid incidentaloma. The incidence of focal thyroid incidentalomas detected on 18F-FDG PET/CT was higher in breast cancer patients than in healthy women (p < 0.01).

The clinicopathological characteristics of primary breast cancer patients with an 18F–FDG PET/CT-detected thyroid incidentaloma
The breast cancer patients with focal thyroid incidentalomas (mean age, 52.9 years) was similar to them without focal thyroid incidentaloma (mean age, 51.2 years) (p = 0.27). The breast cancer histologic types in the group with thyroid incidentalomas were more often ductal carcinoma in situ compared with the group without thyroid incidentalomas (19.8% vs. 14.5%, p = 0.03) (Table 1). The group with thyroid incidentalomas had more ER positivity (56.5% vs. 50.0%), PR positivity (50% vs. 39.3%), and Ki-67 positivity (95.6% vs. 50.2%) than the group without thyroid incidentalomas (p < 0.01) (Table 1). HER2 overexpression was higher in the group without focal thyroid incidentalomas than in the group with focal thyroid incidentalomas (23.2% vs. 15.2%, p < 0.03). Tumor size, number of metastatic lymph nodes, lymphovascular invasion, extent of the intraductal component, and p53 expression were not different between the two groups (Table 1).

The SUVmax and cytological findings in thyroid incidentalomas
Aspiration was performed twice for each nodule. FNAB was performed in 23 of 37 focal thyroid incidentalomas (62.1%) in breast cancer and 5 of 12 thyroid incidentalomas (41%) in healthy subjects. The other 21 thyroid incidentalomas were diagnosed as benign nodular.

Table 1. Clinicopathological characteristics of breast cancer patients according to 18F-FDG PET/CT thyroid incidentaloma

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Thyroid focal incidentaloma (-)</th>
<th>Thyroid focal incidentaloma (+)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)*</td>
<td>51.2 ± 10.5</td>
<td>52.9 ± 9.0</td>
<td>0.27</td>
</tr>
<tr>
<td>Tumor size (cm)*</td>
<td>2.2 ± 1.5</td>
<td>2.05 ± 1.4</td>
<td>0.53</td>
</tr>
<tr>
<td>BMI (m²/kg)*</td>
<td>23.9 ± 3.6</td>
<td>23.5 ± 3.3</td>
<td>0.65</td>
</tr>
<tr>
<td>No. of metastatic LN*</td>
<td>6.1 ± 8.6</td>
<td>8.6 ± 9.4</td>
<td>0.32</td>
</tr>
<tr>
<td>Operation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCS</td>
<td>309 (70.2)</td>
<td>37 (80.4)</td>
<td>0.51</td>
</tr>
<tr>
<td>MRM</td>
<td>131 (29.8)</td>
<td>9 (19.6)</td>
<td></td>
</tr>
<tr>
<td>Histologic type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDC</td>
<td>365 (83.2)</td>
<td>34 (73.2)</td>
<td></td>
</tr>
<tr>
<td>DCIS</td>
<td>64 (14.5)</td>
<td>12 (19.8)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>11 (2.5)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>LVI (+)</td>
<td>77 (17.5)</td>
<td>8 (17.4)</td>
<td>0.98</td>
</tr>
<tr>
<td>EIC (+)</td>
<td>76 (17.3)</td>
<td>9 (19.6)</td>
<td>0.54</td>
</tr>
<tr>
<td>p53 expression (+)</td>
<td>96 (21.8)</td>
<td>10 (21.7)</td>
<td>0.65</td>
</tr>
<tr>
<td>Ki-67 expression (+)</td>
<td>221 (50.2)</td>
<td>44 (93.6)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>ER (+)</td>
<td>224 (50.9)</td>
<td>26 (56.5)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>PR (+)</td>
<td>173 (39.3)</td>
<td>23 (50.0)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HER2 (+)</td>
<td>102 (23.2)</td>
<td>7 (15.2)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

18F-FDG PET/CT = 18F-fluorodeoxyglucose positron emission tomography/computed tomography; BMI = body mass index; LN = lymph node; BCS = breast-conserving surgery; MRM = modified radical mastectomy; IDC = invasive ductal carcinoma; DCIS = ductal carcinoma in situ; LVI = lymphovascular invasion; EIC = extensive intraductal component; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.

*Mean ± SD.
hyperplasia by high-resolution thyroid ultrasonography.

In 46 breast cancer patients with focal thyroid incidentalomas, 35 patients underwent thyroid ultrasonography. The results were as follows: six benign, 11 indeterminate, 11 suspected malignancies, and seven diffuse thyroiditis. Among them, 23 patients underwent ultrasound-guided FNAB, resulting in the diagnosis of 12 benign follicular neoplasms and 11 papillary carcinomas (11/46, 23.9%). The mean SUVmax of the focal incidentalomas confirmed as malignant thyroid carcinomas was $7.1 \pm 10.7$, which was not significantly different from that of the benign focal incidentalomas ($7.1 \pm 6.2$), $(p = 0.99)$. In 17 healthy women with focal thyroid incidentalomas, 12 underwent thyroid ultrasonography, which identified three benign, six indeterminate, and two suspicious malignant nodules. Among them, six patients underwent ultrasound-guided FNAB, resulting in the diagnosis of one benign follicular nodule, three atypia of indeterminate significance, and two suspicious malignant nodules (2/17, 11.7%). All of the malignant thyroid incidentalomas in breast cancer patients and healthy women were diagnosed as papillary thyroid cancer.

**DISCUSSION**

A focal thyroid lesion with significant uptake is likely to be malignant [13], whereas several benign conditions, including nodular hyperplasia, multiple nodular goiter, benign follicular tumor, and chronic thyroiditis, also show a high SUV. Diffusely increased uptake in the thyroid gland favors several thyroidal disorders, including chronic thyroiditis, Graves’ disease, diffuse goiter, and multinodular goiter [14,15]. A strong relationship between breast malignancy and thyroid autoimmune disorders has been found by Giani et al. [16] and confirmed by Smyth et al. [17]. All of these studies have been carried out in breast cancer patients after mastectomy and before beginning any chemohormonal adjuvant therapy. A high prevalence of antithyroid peroxidase autoantibodies has been found in both treated and untreated breast cancer patients and the positive predictive value of serum thyroid peroxidase antibodies (TPO Ab) in breast cancer patients with aggressive disease has been reported [17].

Only Jiskra et al. [18], despite confirming a higher prevalence of TPO Ab in breast cancer patients, found no impact on relapse-free survival and overall survival; this discrepancy could be due to the relatively small number and heterogeneity of breast cancer patients in their study group. Recently Farahati et al. [19] reported a significantly lower frequency of distant metastases in a large cohort of breast cancer patients with serum TPO Ab positivity. The presence of serum TPO Ab, or clinical hypothyroidism, is associated with longer overall survival in patients with invasive breast carcinoma [20]. Overall, the results of previous studies suggest a positive correlation between thyroid disorders and the risk of developing invasive breast carcinoma [17,21].

On $^{18}$F-FDG PET/CT, focal thyroid uptake is incidentally identified in healthy subjects and patients with cancer with an incidence of 0.6% to 3.3%, but in advanced breast cancer patients, Tateishi et al. [22] reported a higher incidence than what was observed in previous studies. Our results in pretreatment breast cancer patients also suggest that a higher incidence of focal thyroid incidentaloma is observed in this patient cohort than in healthy women.

Focal thyroid FDG incidentalomas have been found to have a high risk of being malignant (14%-50%) [1,13,23]. The percentage of malignant thyroid incidentalomas in our study (23.9%) was similar to most previously reported rates [1,12], and lower than other reported data [24]. The current study was a retrospective observation study, and several focal thyroid incidentalomas were no evaluated with FNAB. Because of the high cost of FDG PET and the low incidence of thyroid FDG PET incidentalomas, we cannot use FDG PET prospectively to evaluate the incidence and malignancy rate of thyroid incidentalomas in the general population. A recent study has shown that the CT attenuation pattern of thyroid incidentalomas on dedicated PET/CT could provide additional information for the differentiation of malignant from benign disease [25]. The authors suggested that the $^{18}$F-FDG uptake and the CT attenuation pattern, in addition to the SUV analysis, were helpful in characterizing focal thyroid incidentalomas.

There is also much evidence that estrogen has direct effects in thyroid cell lines originating from normal thyroid gland tissue and in thyroid carcinoma by ER-dependent mechanisms, such as the enhancement of proliferation, modulation of the sodium-iodide symporter and thyroglobulin gene expression, and upregulation of matrix metalloproteinase 9 production [26,27]. We developed a hypothesis in which patients with breast cancer were more frequently diagnosed with thyroid cancers than healthy females. Based on the above findings, ER-positive breast cancers, in particular, may be correlated with thyroid carcinoma. We demonstrated that women with primary breast cancer have a higher incidence of focal thyroid incidentalomas.
than healthy women. We also found that breast cancer with thyroid incidentalomas is most commonly ER-positive breast cancer or ductal carcinoma in situ.

Although several studies [28,29] have investigated the expression of ER subtypes in thyroid cancers without consistent results as of yet, Huang et al. [30] reported that ERα may be a useful immunohistochemical marker for the differential diagnosis of papillary thyroid carcinoma. They also showed an association of the ER subtype expression with Ki-67 positivity and mutant p53 in female papillary thyroid carcinoma patients of reproductive age, suggesting that estrogen-activated ERα may mediate the stimulatory effects on papillary thyroid carcinoma growth and progression; in contrast, ERβ1 has some inhibitory effects. This study was not a prospective study of the relationship between breast cancer and thyroid disease or thyroid malignancy, resulting in a limited ability to estimate these relationships. In addition, further studies are required to evaluate the immunohistochemical markers, such as Ki-67 positivity, ER subtypes, and mutant p53, in both thyroid cancers with focal thyroid uptake incidentalomas and in breast cancer patients with focal thyroid incidentalomas.

In conclusion, this study has demonstrated that focal thyroid incidentalomas are more frequently detected with 18F-fluorodeoxyglucose positron emission tomography in patients with breast cancer than in healthy women. Focal thyroid nodules incidentally found with 18F-fluorodeoxyglucose PET/CT in breast cancer patients have a high risk of malignancy. ER positivity, Ki-67 positivity, and ductal carcinoma in situ correlated positively with 18F-FDG PET/CT-detected focal thyroid incidentalomas. Additional studies need to systematically investigate ER expression in female papillary thyroid cancer patients with concurrent breast cancer and to further analyze the relationship of ER expression with important clinicopathological factors and biological markers (Ki-67, vascular endothelial growth factor) in Korea.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

Breast Cancer and Focal Thyroid Incidentaloma


18. Iskra J, Barkmanova J, Lamanova Z, Lánská V, Smutek D, Potlukova E, et al. Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep 2007;18:1603-11.


